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BACKGROUND
MenB-FHbp is a licensed meningococcal B vaccine targeting factor H–binding protein. 
Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against 
diverse strains of group B meningococcus.
METHODS
We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or 
hepatitis A virus vaccine and saline and assigned 3304 young adults (18 to 25 years of age) 
to receive MenB-FHbp or saline at baseline, 2 months, and 6 months. Immunogenicity was 
assessed in serum bactericidal assays that included human complement (hSBAs). We used 
14 meningococcal B test strains that expressed vaccine-heterologous factor H–binding 
proteins representative of meningococcal B epidemiologic diversity; an hSBA titer of at least 
1:4 is the accepted correlate of protection. The five primary end points were the proportion 
of participants who had an increase in their hSBA titer for each of 4 primary strains by a 
factor of 4 or more and the proportion of those who had an hSBA titer at least as high as 
the lower limit of quantitation (1:8 or 1:16) for all 4 strains combined after dose 3. We also 
assessed the hSBA responses to the primary strains after dose 2; hSBA responses to the 
10 additional strains after doses 2 and 3 were assessed in a subgroup of participants only. 
Safety was assessed in participants who received at least one dose.
RESULTS
In the modified intention-to-treat population, the percentage of adolescents who had an 
increase in the hSBA titer by a factor of 4 or more against each primary strain ranged from 
56.0 to 85.3% after dose 2 and from 78.8 to 90.2% after dose 3; the percentages of young 
adults ranged from 54.6 to 85.6% and 78.9 to 89.7%, after doses 2 and 3, respectively. 
Composite responses after doses 2 and 3 in adolescents were 53.7% and 82.7%, respec-
tively, and those in young adults were 63.3% and 84.5%, respectively. Responses to the 
4 primary strains were predictive of responses to the 10 additional strains. Most of 
those who received MenB-FHbp reported mild or moderate pain at the vaccination site.
CONCLUSIONS
MenB-FHbp elicited bactericidal responses against diverse meningococcal B strains 
after doses 2 and 3 and was associated with more reactions at the injection site than 
the hepatitis A virus vaccine and saline. (Funded by Pfizer; ClinicalTrials.gov numbers, 
NCT01830855 and NCT01352845.)
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Neisseria meningitidis causes invasive meningococcal disease, which occurs pre-dominantly in infants, adolescents, and 
young adults.1 Patients frequently present with 
symptoms similar to those of meningitis or septi-
cemia. Death occurs in up to 15% of infected 
persons,1 and up to 20% of survivors have long-
term impairments.2,3
Serogroup B (meningococcal B) accounts for 
a large proportion of invasive meningococcal 
disease in the United States, Europe, and other 
regions.4-8 Capsular polysaccharide-based vaccines 
can prevent infection with serogroups A, C, W, 
and Y, but these vaccines are unsuitable for sero-
group B disease because the meningococcal B 
capsular polysaccharide is not immunogenic.9 Vac-
cines that target the outer-membrane vesicle have 
effectively controlled epidemics caused by single 
meningococcal B strains,10,11 but such vaccines are 
generally ineffective when used against strains 
other than the targeted strain. Consequently, ef-
forts to develop a meningococcal B vaccine have 
focused on surface-exposed proteins with the in-
tention of eliciting protective bactericidal anti-
bodies across diverse global invasive strains.
LP2086, a conserved, surface-exposed bacterial 
lipoprotein that functions as a human complement 
factor H–binding protein, has been identified as a 
vaccine target.12 Epidemiologic studies have sug-
gested that a vaccine containing a factor H–bind-
ing protein variant from each of the two immuno-
logically distinct protein subfamilies (A and B) 
protects against diverse, disease-causing menin-
gococcal B strains.13,14 These findings spurred the 
development of bivalent rLP2086, or MenB-FHbp 
(Trumenba, Pfizer), which consists of one factor 
H–binding protein variant from each subfamily. 
On the basis of data from phase 1 and 2 stud-
ies,15-21 MenB-FHbp was the first meningococcal 
B vaccine licensed in the United States; licensure 
of 4CMenB (Bexsero, Novartis), the other menin-
gococcal B vaccine available in the United States, 
followed. The Advisory Committee on Immuniza-
tion Practices recommends meningococcal B vac-
cination for at-risk persons 10 years of age and 
older and recommends that vaccination be consid-
ered for persons 16 to 23 years of age for protec-
tion against meningococcal B disease.22,23
Large-scale efficacy studies of meningococcal 
vaccines are challenging owing to the low inci-
dence of disease, which precludes the use of clini-
cal disease outcomes. Because protection against 
invasive meningococcal disease requires the use of 
serum bactericidal antibodies against meningococ-
cal capsular polysaccharides or protein antigens,1 
vaccine effectiveness is often inferred by measur-
ing bactericidal antibodies in serum bactericidal 
assays with human complement (hSBAs). An hSBA 
titer of at least 1:4 is the accepted correlate of pro-
tection.24-27
MenB-FHbp is designed to afford broad protec-
tion against diverse disease-causing strains. Al-
though each invasive meningococcal B strain ex-
presses only one factor H–binding protein variant, 
numerous such variants have been identified. 
Therefore, an assessment of vaccine coverage with 
hSBAs requires an approach to testing strain se-
lection that is different from that used for poly-
saccharide vaccines, which use only one strain to 
assess individual serogroup coverage. Four primary 
test strains that met specific requirements (repre-
sentative factor H–binding protein expression and 
epidemiologic diversity among circulating strains 
and expression of such sequence variants differ-
ent from vaccine antigens) were selected without 
bias.28 To supplement the responses to hSBA ob-
tained with primary strains and to evaluate wheth-
er these responses predicted responses against 
other meningococcal B strains, additional, anti-
genically diverse meningococcal B test strains that 
express prevalent factor H–binding protein vari-
ants were selected in a manner similar to that used 
for the primary strains and were used in hSBAs. 
We conducted two phase 3 randomized, controlled, 
observer-blinded, multicenter trials to assess the 
immunogenicity and safety of MenB-FHbp in 
healthy adolescents and young adults.
Me thods
Trial Design
Randomization was stratified according to geo-
graphic regions, and trials were completed in 10 
countries. Enrollment in the trial involving adoles-
cents occurred in Canada (114 participants), the 
Czech Republic (116), Finland (590), Germany 
(184), Italy (185), Poland (440), the United Kingdom 
(161), and the United States (1806). This trial was 
conducted from April 18, 2013, through June 17, 
2015. Enrollment in the trial involving young adults 
occurred in Canada (367 participants), Denmark 
(451), Finland (454), Poland (83), Spain (301), and 
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the United States (1648). This trial was conducted 
from May 3, 2013, through July 9, 2015.
Adolescents underwent randomization in a ra-
tio of 5:2:2:3 to receive one of three manufacturing 
lots (hereafter referred to as lots) of MenB-FHbp 
or hepatitis A virus vaccine (Havrix, GlaxoSmith-
Kline) and saline, and young adults underwent 
randomization in a ratio of 3:1 to receive MenB-
FHbp or saline (Fig. S1 in the Supplementary Ap-
pendix, available with the full text of this article at 
NEJM.org). Staff members who administered the 
vaccines were aware of trial-group assignments 
and did not assess safety; other trial personnel, the 
sponsor (Pfizer), and participants were unaware of 
trial-group assignment.
The sponsor was involved in the trial design 
and in data collection and analysis. All the authors 
had access to the data, vouch for the accuracy and 
completeness of the data, and made the decision 
to submit the manuscript for publication. The first 
draft of the manuscript was developed by medical 
writers funded by the sponsor under the direction 
of the authors.
Trial Objectives
The primary immunogenicity objectives included 
the assessment of immune responses as measured 
in hSBA titers to 4 primary test strains expressing 
factor H–binding protein variants A22, A56, B24, 
and B44 (Fig. 1)13 1 month after the administra-
tion of dose 3 to satisfy the five primary end points 
related to immunogenicity. Key secondary objec-
tives included the assessment of hSBA responses 
to 4 primary strains 1 month after the adminis-
tration of dose 2 and responses to 10 additional 
strains (expressing factor H–binding protein vari-
ants A06, A07, A12, A15, A19, A29, B03, B09, B15, 
and B16 [Fig. 1]) 1 month after the administration 
of dose 3. Primary safety objectives were evaluated 
on the basis of comparisons of safety outcomes 
between participants who received MenB-FHbp 
and controls.
Trial Participants
To be included in the trials, participants had to be 
healthy. Participants in the trial involving adoles-
cents had to be between 10 to 18 years of age, and 
Figure 1. Phylogenetic Tree for Factor H–Binding Protein.
A total of 4 primary and 10 additional meningococcal B (MenB) test strains that expressed vaccine-heterologous factor H–binding pro-
tein (fHbp) and that were representative of the epidemiologic diversity of MenB were used in serum bactericidal assays that included 
human complement (hSBAs) in the clinical development of the MenB-FHbp vaccine. Participant responses to the 4 primary test strains 
(expressing fHbp variants A22, A56, B24, and B44) were predictive of responses to the 10 additional strains. Percentages shown in the 
phylogenetic tree are the suggested subgroup prevalence as determined with the use of the percentage of the 1263 isolates in the MenB 
hSBA strain pool; in each case, the first percentage indicates prevalence in the United States and the second indicates prevalence in the 
United States and Europe combined.28
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those in the trial involving young adults had to 
be 18 to 25 years of age. All the participants had 
to comply with trial procedures. Written informed 
consent was obtained from the participants, their 
parents, or otherwise authorized representatives 
before enrollment. Details regarding the criteria 
used for trial inclusion and exclusion and the 
recruitment method are available in the Supple-
mentary Appendix and the protocol, available at 
NEJM.org.
Interventions
Investigational products were administered in-
tramuscularly into the upper deltoid muscle at 
baseline and at 2 and 6 months. MenB-FHbp and 
hepatitis A virus vaccine were formulated as de-
scribed in the Supplementary Appendix and else-
where.29,30 Age-specific doses of hepatitis A virus 
vaccine were supplied in accordance with country-
specific guidelines. Saline was administered at a 
dose of 0.5 ml. Participants provided approxi-
mately 20 ml of blood for hSBAs before receiving 
dose 1 and approximately 1 month after receiving 
doses 2 and 3.
Immunogenicity
The hSBAs were based on assays described by the 
World Health Organization31 and Borrow et al.25 
and were performed as reported previously.19 Pri-
mary and additional meningococcal B test strains 
are described in Figure 1 and in the Supplemen-
tary Appendix. The modified intention-to-treat 
population included all the participants who had 
undergone randomization and who had at least 
one valid and determinate assay result related to 
the analysis. The per-protocol population includ-
ed eligible participants who had undergone ran-
domization, received the correct investigational 
product, had baseline and postvaccination blood 
draws within the correct intervals, had valid and 
determinate assay results, and had no major vio-
lation of the protocol, a procedure that was con-
sistent with the conduct of preventive vaccine tri-
als in which the objective is estimation of the 
biologic efficacy of the vaccine and not assess-
ment of a therapeutic effect.32
Four primary end points were the proportion 
of participants who had an increase in the hSBA 
titer by a factor of at least 4 for each of the four 
primary meningococcal B test strains from base-
line to 1 month after receipt of dose 3 (see the 
Supplementary Appendix). The fifth primary end 
point was the proportion of participants who had 
an hSBA titer that reached or exceeded the lower 
limit of quantitation for all four primary menin-
gococcal B test strains combined 1 month after 
the receipt of dose 3 (composite response). The 
95% confidence interval for the lower limit for 
each primary end point was assessed (see the 
Supplementary Appendix); success was declared 
when the lower limits of the 95% confidence in-
terval were higher than the defined thresholds. In 
the trial involving adolescents, the thresholds for 
A22, A56, B24, and B44 for an increase in the 
hSBA titer by a factor of at least 4 were 75%, 85%, 
65%, and 60%, respectively; the threshold for the 
composite response was 75%. In the trial involv-
ing young adults, the corresponding thresholds 
for an increase in the hSBA titer by a factor of at 
least 4 were 55%, 85%, 50%, and 60%, and the 
threshold for the composite response was 60%. 
Null and alternative hypotheses are defined in 
the Supplementary Appendix.
The lower limit of quantitation for strains ex-
pressing factor H–binding protein variants A07, 
A15, A29, A56, B03, B09, B15, B16, B24, and B44 
was 1:8, and the lower limit of quantitation for 
strains expressing A06, A12, A19, and A22 was 
1:16. (Details regarding the determination of lower 
limit of quantitation are provided in the Supple-
mentary Appendix.)
There were several additional end points for 
immunogenicity. For the primary strains, these 
end points included the proportion of partici-
pants who had an increase in the hSBA titer by 
a factor of 4 or more and a composite response 
from baseline to 1 month after receiving dose 2. 
For all strains, these end points included the pro-
portion of participants who had an hSBA titer 
that was greater than or equal to the lower limit 
of quantitation for meningococcal B test strains at 
baseline and 1 month after receiving doses 2 and 
3, the proportion who had a defined hSBA titer at 
baseline and 1 month after receiving doses 2 and 
3, and hSBA geometric mean titers at baseline 
and 1 month after doses 2 and 3.
Safety
Safety was evaluated for all the participants who 
received at least one dose of an investigational 
product. Data regarding injection-site reactions 
and systemic events, including fever, were collected 
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in an electronic diary for the first 7 days after each 
injection. Unsolicited adverse events were report-
ed by investigators and assessed with regard to 
onset, duration, severity, relationship to the inves-
tigational product, and seriousness. Local reac-
tions and systemic events may also have been re-
ported as unsolicited adverse events. Immediate 
adverse events (those occurring within 30 minutes 
after injection) were reported. Among all adverse 
events, serious adverse events, medically attended 
adverse events, and newly diagnosed chronic med-
ical conditions were assessed for a period of 
6 months after the administration of dose 3. See 
the Supplementary Appendix for additional details.
Statistical Analysis
In the adolescent group, we determined that the 
inclusion of 880 participants in the MenB-FHbp 
group who were able to be evaluated and who re-
ceived lot 1 would provide a power of more than 
99% for the primary immunogenicity hypotheses 
(see the Supplementary Appendix for details). 
Thus, a total of 3600 participants (with 1500 in 
the MenB-FHbp group receiving lot 1) were to be 
enrolled, with a randomization ratio of 5:2:2:3 
(lot 1:lot 2:lot 3:heptitis A vaccine and saline). In 
the young adult group, we determined that includ-
ing 1700 participants in the MenB-FHbp group 
who were able to be evaluated would provide 
power of more than 99% for the primary immu-
nogenicity hypotheses, for a total enrollment of 
3300 participants. The randomization ratio for 
MenB-FHbp to saline was 3:1, and there was an 
assumption that 30% of enrollees could not be 
evaluated. The overall type I error level was 5% 
for end points related to primary objectives. No 
control for a type I error level was conducted for 
end points related to secondary objectives.
The observed proportions of participants were 
summarized with exact two-sided 95% confidence 
intervals with the use of the Clopper–Pearson 
method. All hSBA titers and geometric mean ti-
ters were computed with two-sided 95% confi-
dence intervals constructed by means of the back 
transformation of confidence limits computed for 
the mean of logarithmically transformed assay 
data on the basis of Student’s t-distribution. Post 
hoc analyses of positive predictive values deter-
mined the association between primary and ad-
ditional test strains that expressed factor H–bind-
ing proteins in the same subfamily. Safety was 
summarized descriptively. Additional details re-
garding the statistical analysis are provided in 
the Supplementary Appendix.
R esult s
Participants
Among the 3596 adolescents who underwent ran-
domization, 3272 (91.0%) completed the vaccina-
tion phase. Among the 3304 young adults who 
underwent randomization, 2474 (74.9%) completed 
the vaccination phase (Fig. 2). In each trial, the 
demographic characteristics of the MenB-FHbp 
group and the control group were similar (Table 1).
Immunogenicity
In the two trials, the induction of broadly protec-
tive antibodies by MenB-FHbp was inferred be-
cause all five primary end points for immunoge-
nicity were met. In the modified intention-to-treat 
population, after dose 3, the percentages of par-
ticipants in whom the hSBA titers against the 
four primary test strains increased by a factor of 
at least 4 ranged from 78.8 to 90.2% among ado-
lescents and from 78.9 to 89.7% among young 
adults, depending on the strain tested (see Fig. 3A 
and 3B, and Table S2 in the Supplementary Ap-
pendix for results in the modified intention-to-
treat population, and see Fig. S2A and Table S3 
in the Supplementary Appendix for results in the 
per-protocol population); percentages in the con-
trol groups were 11.0% or less. Composite hSBA 
responses were 82.7% in adolescents and 84.5% 
in young adults after dose 3 of MenB-FHbp and 
7.4% or less in controls. Among the recipients of 
MenB-FHbp, after dose 2, 56.0 to 85.3% of ado-
lescents and 54.6 to 85.6% of young adults had 
hSBA titers that increased by a factor of 4 or more, 
and 53.7% of adolescents and 63.3% of young 
adults had a composite response.
Before vaccination, most participants had hSBA 
titers below the lower limit of quantitation (1:8 or 
1:16, depending on strain) (Fig. 3C and 3D, and 
Tables S2 and S3 and Fig. S2B in the Supplemen-
tary Appendix). Among the recipients of MenB-
FHbp, the percentages with an hSBA titer that 
was equal to or greater than the lower limit of 
quantitation for the primary strains were 64.0 to 
99.0% among the adolescents and 67.3 to 97.4% 
among the young adults after dose 2; the corre-
sponding values after dose 3 were 86.4 to 99.5% 
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and 87.1 to 99.3%. The percentages of partici-
pants who had defined levels of hSBA titers for 
primary strains after doses 2 and 3 were sub-
stantially higher among MenB-FHbp recipients 
than among controls (Fig. S3 in the Supplemen-
tary Appendix). The hSBA geometric mean titers 
increased after each dose of MenB-FHbp (Fig. 3E 
and 3F, and Tables S2 and S3 and Fig. S2C in the 
Supplementary Appendix). Controls showed neg-
ligible hSBA responses. Similar results were ob-
tained for all primary immunogenicity analyses 
in the per-protocol and modified intention-to-treat 
populations (Table S4 in the Supplementary Ap-
pendix). Sensitivity analyses that were conducted 
to explore the effects of missing data were com-
pleted. Modeling approaches that used partial 
data yielded conclusions that were similar to the 
primary findings with respect to the hSBA geo-
metric mean titer and to the increase in titer by 
a factor of 4 or more (Table S5 in the Supple-
mentary Appendix).
For the additional meningococcal B strains 
tested with the use of serum samples from a 
random subgroup of participants, percentages of 
participants with an hSBA titer that was at least 
as high as the lower limit of quantitation, per-
centages with a defined hSBA titer, and percent-
ages with an hSBA geometric mean titer increased 
substantially from baseline to 1 month after re-
ceipt of doses 2 and 3 (Fig. 3C through 3F, and 
Tables S2 and S3, Fig. S2B and S2C, and Fig. S3 
in the Supplementary Appendix).
Figure 2. Disposition of Participants in Both Trials.
The vaccination phase represents the time from the administration of dose 1 to 1 month after the administration of dose 3. The reasons 
for withdrawal from both trials are summarized in Table S1 in the Supplementary Appendix. The modified intention-to-treat population 
included all participants who underwent randomization and who had at least one valid and determinate assay result related to the analy-
sis. The per-protocol population included all participants who underwent randomization, received the correct investigational product, 
and had baseline and postvaccination blood draws collected within correct intervals, valid and determinate assay results, and no other 
major protocol violations. HAV denotes hepatitis A virus vaccine.
Adolescents Young Adults
3596 Participants were enrolled
and underwent randomization 
3304 Participants were enrolled
and underwent randomization 
1509 Were assigned to
MenB-FHbp, Lot 1
140 Withdrew
600 Were assigned to
MenB-FHbp, Lot 2
589 Were assigned to
MenB-FHbp, Lot 3
898 Were assigned
 to HAV and saline
2480 Were assigned
 to MenB-FHbp
824 Were assigned
 to saline
1508 Received
injection 1
1436 Received
injection 2
1379 Received
injection 3
2471 Received
injection 1
2169 Received
injection 2
1889 Received
injection 3
822 Received
injection 1
733 Received
injection 2
649 Received
injection 3
897 Received
injection 1
862 Received
injection 2
837 Received
injection 3
587 Received
injection 1
564 Received
injection 2
537 Received
injection 3
598 Received
injection 1
571 Received
injection 2
546 Received
injection 3
55 Withdrew 60 Withdrew 69 Withdrew 641 Withdrew 189 Withdrew
1369 Completed the
vaccination phase
545 Completed the
vaccination phase
529 Completed the
vaccination phase
829 Completed the
vaccination phase
1839 Completed the
vaccination phase
635 Completed the
vaccination phase
1353 Completed
the trial
537 Completed
the trial
521 Completed
the trial
815 Completed
the trial
1800 Completed
the trial
619 Completed
the trial
1507 Were included
in the modified
intention-to-treat
population
598 Were included
in the modified
intention-to-treat
population
587 Were included
in the modified
intention-to-treat
population
898 Were included
in the modified
intention-to-treat
population
2471 Were included
in the modified
intention-to-treat
population
822 Were included
in the modified
intention-to-treat
population
1279 Were included
in the per-protocol
population
519 Were included
in the per-protocol
population
493 Were included
in the per-protocol
population
768 Were included
in the per-protocol
population
1723 Were included
in the per-protocol
population
582 Were included
in the per-protocol
population
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Analyses of positive predictive value assessed 
whether observed hSBA responses to primary 
strains predicted immune responses to additional 
strains that expressed factor H–binding proteins 
from the same subfamily. The higher the positive 
predictive values, the more likely it was that the 
responses to the primary strains predicted re-
sponses to diverse meningococcal B strains. 
Among adolescents, the positive predictive values 
for subfamily A strains after doses 2 and 3 were 
64.4 to 100% and 75.6 to 99.6%, respectively, and 
for subfamily B strains the corresponding values 
were 78.9 to 100% and 86.4 to 99.6% (Table S6 
in the Supplementary Appendix). Among young 
adults, the corresponding values were 61.6 to 
100% and 72.2 to 100% for subfamily A strains 
and 70.0 to 100.0% and 80.5 to 98.8% for sub-
family B strains.
Injection-Site Reactions
Pain was the most common reaction in the two 
trial groups (Fig. 4A, and Table S7 in the Supple-
mentary Appendix). Among the recipients of 
MenB-FHbp, the frequency of the reaction was 
generally highest after dose 1. Six adolescents 
(all MenB-FHbp recipients) and three young adults 
(two MenB-FHbp recipients and one saline recipi-
ent) withdrew because of local reactions. Few 
participants (≤1.1%) reported increased severity 
of reaction with subsequent doses. Among the 
MenB-FHbp recipients, the median onset of the 
reaction was 1 to 2 days, and the median duration 
was 1 to 3 days.
Systemic Events
Headache and fatigue were the most common 
systemic events among both adolescents and 
young adults (Fig. 4B, and Table S7 in the Supple-
mentary Appendix). The frequency of systemic 
events was highest after dose 1 in all groups.
One adolescent recipient of MenB-FHbp with-
drew because of a systemic event (chills). Four 
young adults withdrew because of systemic events 
(three MenB-FHbp recipients because of fever, 
Characteristic Adolescents Young Adults
MenB-FHbp, 
Lot 1 
(N = 1508)
MenB-FHbp, 
Lot 2 
(N = 598)
MenB-FHbp, 
Lot 3 
(N = 587)
HAV and Saline 
(N = 897)
MenB-FHbp 
(N = 2471)
Saline 
(N = 822)
Age at first vaccination — yr
Mean 13.9±2.6 14.0±2.6 13.9±2.6 13.9±2.6 21.5±2.1 21.5±2.2
Median† 14 14 14 14 21 22
Range 10–19 10–18 10–18 10–18 18–25 18–25
Male — no. (%) 771 (51.1) 312 (52.2) 313 (53.3) 454 (50.6) 1019 (41.2) 340 (41.4)
Race — no. (%)‡
White 1307 (86.7) 526 (88.0) 522 (88.9) 779 (86.8) 1880 (76.1) 627 (76.3)
Black 129 (8.6) 46 (7.7) 39 (6.6) 78 (8.7) 515 (20.8) 169 (20.6)
Asian 7 (0.5) 2 (0.3) 4 (0.7) 3 (0.3) 38 (1.5) 13 (1.6)
Other 65 (4.3) 24 (4.0) 22 (3.7) 37 (4.1) 38 (1.5) 13 (1.6)
Ethnic group — no. (%)‡
Non-Hispanic or non-Latino 1428 (94.7) 563 (94.1) 549 (93.5) 841 (93.8) 2042 (82.6) 686 (83.5)
Hispanic or Latino 80 (5.3) 35 (5.9) 38 (6.5) 56 (6.2) 427 (17.3) 136 (16.5)
Unknown 0 0 0 0 2 (0.1) 0
*  Plus–minus values are means ±SD. HAV denotes hepatitis A virus vaccine. Percentages may not total 100 because of rounding.
†  One participant in the trial involving adolescents was 18 years old at randomization, but the first vaccination was delayed because of antibi-
otic use.
‡  Race and ethnic group were reported by the participants. Two participants in the trial involving young adults were unwilling to disclose race 
or ethnic group. For analysis purposes, the participants have been pooled with participants who reported race as “other” and ethnic group 
is considered to be “unknown.”
Table 1. Demographic Characteristics of the Trial Participants.*
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mild arthralgia, and moderate myalgia and one 
saline recipient because of mild chills). Among 
the MenB-FHbp recipients, the median onset of 
symptoms was 1 to 5 days, and the median dura-
tion was 1 to 2 days.
One adolescent in the control group had a 
fever higher than 40.0°C after dose 3 (dose 2 of 
the hepatitis A virus vaccine). One young adult 
who received MenB-FHbp had a fever of 40.7°C 
after dose 3, which resolved after day 1. Among 
adolescents receiving MenB-FHbp, antipyretics 
were used by 862 of 2686 (32.1%); among controls, 
antipyretics were used by 180 of 893 (20.2%). 
Among the young adults, antipyretics were used 
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in 606 of 2438 (24.9%) of those receiving MenB-
FHbp and in 121 of 808 (15.0%) of controls.
Adverse Events
The overall frequency of adverse events was 
similar in the MenB-FHbp group and the control 
group (Table 2, and Tables S7 and S8 in the 
Supplementary Appendix). Most adverse events 
and most vaccine-related adverse events that oc-
curred within 30 days after any dose were mild 
to moderate in severity. Among the young adults, 
after any vaccination, a greater number of these 
events were reported by recipients of MenB-FHbp 
than by controls (4.5% vs. 2.3%). Among the young 
adults, the between-group difference in reporting 
vaccine-related adverse events of any type was 
driven by local reactions and systemic events 
reported in the clinical database in addition to 
those captured in participant-reported electronic 
diaries. Among adolescents, serious adverse events 
were reported by 1.9% of MenB-FHbp recipients 
and 2.5% of control recipients; no vaccine-related 
serious adverse events were reported. Among the 
young adults, serious adverse events were report-
ed by 1.3% of MenB-FHbp recipients and 1.3% of 
control recipients; among MenB-FHbp recipients, 
three participants (0.1%) reported vaccine-related 
serious adverse events.
Discussion
Broadly protective hSBA responses were observed 
in both of these phase 3 trials after three doses 
of MenB-FHbp (administered at baseline and at 
2 and 6 months), and primary immunogenicity 
end points were met. Immune responses were also 
reported after the first and second doses. These 
results are consistent with those from phase 2 
licensure trials.15-21 Immunogenicity was report-
ed on the basis of hSBA titers against an antigeni-
cally and epidemiologically diverse panel of pri-
mary test strains. These strains were representative 
of disease-causing meningococcal B isolates ex-
pressing factor H–binding proteins that are dif-
ferent from vaccine antigens. Immunogenicity end 
points required titers above the accepted correlate 
of protection for invasive meningococcal disease 
(i.e., ≥1:4). The requirement for an increase in 
the hSBA titer by a factor of 4 or more also al-
lowed for the assessment of the added benefit of 
vaccination in populations in whom naturally 
acquired baseline immunity may be higher than 
the norm. Furthermore, the composite responses 
simultaneously measured the hSBA response to 
all four primary strains combined, which provided 
an assessment of the ability of vaccine-elicited an-
tibodies to recognize factor H–binding proteins 
across diverse meningococcal B strains. More 
than 99% of the participants had a response 
(hSBA titer ≥ the lower limit of quantitation) to 
at least one meningococcal B test strain.
In polysaccharide-conjugate and outer-mem-
brane–vesicle vaccines, the antigenic structure of 
Figure 3 (facing page). Immunogenicity End Points  
in Adolescents and Young Adults.
Panel A shows the percentage of participants in the 
adolescent group who had a baseline serum bacteri-
cidal assay with human complement (hSBA) titer for 
each meningococcal B primary test strain that in-
creased by a factor of 4 or more or a composite re-
sponse (i.e., hSBA titers that reached or exceeded the 
lower limit of quantitation [LLOQ] for all four primary 
meningococcal B test strains combined) at prevacci-
nation and at 1 month after dose 2 and 1 month after 
dose 3. Panel B shows the same percentages for par-
ticipants in the young adult group. Panel C shows the 
percentages of adolescents with hSBA titers greater 
than or equal to the prespecified limits (LLOQ, 1:8 or 
1:16) for the primary meningococcal B strains and for 
additional test strains. Panel D shows the same per-
centages for the young adult group. Panels E and F 
show hSBA geometric mean titers for the adolescent 
group and the young adult group, respectively. Data 
are from the modified intention-to-treat population. 
The increase in the hSBA titer by a factor of 4 or more 
is defined as follows: for participants with a baseline 
hSBA titer below the limit of detection (LOD) (hSBA 
titer <1:4), a response is defined as an hSBA titer 
greater than or equal to 1:16 or the LLOQ (whichever 
titer is higher); for participants with a baseline hSBA 
titer that is greater than or equal to the LOD and lower 
than the LLOQ, a response is defined as an hSBA titer 
that is at least four times as high as the LLOQ; and for 
participants with a baseline hSBA titer that is greater 
than or equal to the LLOQ, a response is defined as 
an hSBA titer that is at least four times as high as the 
baseline titer. Data for the adolescents trial are from 
MenB-FHbp lot 1 only, for which there was a power of 
more than 99% for the primary immunogenicity hy-
potheses. Observed proportions of participants were 
summarized with the use of exact two-sided 95% con-
fidence intervals, in accordance with the Clopper–
Pearson method. I bars represent 95% confidence in-
tervals. GMT denotes geometric mean titer, and HAV 
hepatitis A virus vaccine. For additional information, 
including participant numbers, see the Supplementary 
Appendix.
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vaccine antigens and those on targeted strains is 
the same, which means that selection of multiple 
hSBA strains is not required to establish vaccine 
coverage. In contrast, several hundred distinct 
variants of factor H–binding protein have been 
identified on meningococcal B strains, which 
means that the approach to the selection of hSBA 
test strains to assess MenB-FHbp must be unbi-
ased and must also support the demonstration 
of broader vaccine coverage.28 Four primary 
meningococcal B test strains reflecting factor 
H–binding protein surface expression, sequence 
diversity, and overall prevalence of disease-caus-
ing variants in Europe and the United States were 
identified. Responses from an additional 10 test 
strains provided support for the breadth of re-
sponse observed with the primary strains. To-
gether, these 14 test strains capture the sequence 
Characteristic of Event Adolescents Young Adults
MenB-FHbp† 
(N = 2693)
HAV and Saline 
(N = 897)
MenB-FHbp 
(N = 2471)
Saline 
(N = 822)
number (percent)
Occurred during vaccination phase‡ 1097 (40.7) 392 (43.7) 771 (31.2) 256 (31.1)
Mild 673 (25.0) 242 (27.0) 494 (20.0) 175 (21.3)
Moderate 610 (22.7) 197 (22.0) 364 (14.7) 116 (14.1)
Severe 89 (3.3) 35 (3.9) 71 (2.9) 16 (2.0)
Related 52 (1.9) 16 (1.8) 114 (4.6) 20 (2.4)
Occurred within 30 days after any  
vaccination
682 (25.3) 240 (26.8) 523 (21.2) 155 (18.9)
Mild 375 (13.9) 143 (15.9) 313 (12.7) 104 (12.7)
Moderate 348 (12.9) 111 (12.4) 234 (9.5) 68 (8.3)
Severe 53 (2.0) 20 (2.2) 50 (2.0) 10 (1.2)
Related 52 (1.9) 15 (1.7) 110 (4.5) 19 (2.3)
Occurred within 30 min after any  
vaccination
10 (0.4) 3 (0.3) 11 (0.4) 7 (0.9)
Serious‡§ 51 (1.9) 22 (2.5) 33 (1.3) 11 (1.3)
Related 0 0 3 (0.1) 0
Newly diagnosed chronic condition§ 15 (0.6) 10 (1.1) 10 (0.4) 2 (0.2)
Mild 6 (0.2) 7 (0.8) 3 (0.1) 0
Moderate 8 (0.3) 3 (0.3) 7 (0.3) 2 (0.2)
Severe 1 (0.04) 0 0 0
Related 0 0 0 0
Medically attended adverse event§ 872 (32.4) 319 (35.6) 541 (21.9) 174 (21.2)
Mild 509 (18.9) 193 (21.5) 306 (12.4) 104 (12.7)
Moderate 543 (20.2) 183 (20.4) 271 (11.0) 88 (10.7)
Severe 57 (2.1) 21 (2.3) 44 (1.8) 6 (0.7)
Related 22 (0.8) 3 (0.3) 17 (0.7) 5 (0.6)
*  HAV denotes hepatitis A virus vaccine. Adverse events were unsolicited events as reported by the investigator. Local reactions and systemic
events could have also been reported as unsolicited adverse events. Serious adverse events were any untoward medical occurrences at any
dose that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in congenital anomaly
or birth defect, or were related to lack of efficacy in an approved indication. Severe events were those that interfered significantly with the
participant’s usual function.
†  Data are for participants who received vaccine from lots 1, 2, and 3.
‡  Information on serious adverse events is provided in Table S8 in the Supplementary Appendix.
§  These events occurred throughout the trial.
Table 2. Participants Reporting at Least One Adverse Event.*
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diversity observed across the two factor H–bind-
ing protein subfamilies (Fig. 1). Furthermore, by 
demonstrating with positive predictive value anal-
yses the ability of 4 primary test strains to pre-
dict coverage with the use of 10 additional test 
strains, our findings provide assurance that ob-
served immune responses to the primary strains 
are representative and indicative of vaccine re-
sponses to diverse disease-causing meningococ-
cal B strains.
The method that is used to assess breadth of 
coverage of meningococcal B vaccines is an im-
portant consideration in determining their po-
tential for the prevention of endemic disease and 
the spread of outbreaks. This view was high-
lighted in a recent study of the 4CMenB vaccine 
in which hSBA responses to a recent university 
outbreak strain were compared with vaccine 
reference strains expressing vaccine-homologous 
antigens.33 In contrast to our trial, other trials of 
4CMenB predominantly used the Meningococcal 
Antigen Typing System (MATS) to estimate cov-
erage.34,35 MATS, which uses pooled serum data, 
consists of three enzyme-linked immunosorbent 
assays to detect three of the four 4CMenB anti-
gens: factor H–binding protein, neisserial hepa-
rin-binding antigen, and neisserial adhesin A. The 
fourth antigen, porin protein A (PorA), is evaluated 
with the use of genotyping.34,35 Basta and col-
leagues reported that a lower proportion of par-
ticipants had a response to 4CMenB when hSBAs 
were performed with the outbreak strain than 
when the assays were performed with the vaccine 
reference strain, which expressed vaccine-homol-
ogous antigens (66% for the outbreak strain vs. 
87 to 100% for the vaccine reference strain).33 The 
response against this outbreak strain was also not 
as strong as that predicted by MATS in earlier 
trials.33 Similar findings have been reported in 
another trial.36
The limitations of our trials are that vaccine 
efficacy could not be assessed with the use of a 
clinical disease end point because of the relatively 
low incidence of meningococcal B disease and the 
fact that only short-term antibody responses were 
assessed, which precluded the assessment of an-
tibody persistence. However, the short-term 
hSBA response, the accepted surrogate of vaccine 
efficacy, has been used to license other menin-
gococcal vaccines, including meningococcal B 
outer-membrane vesicle vaccines, and post-licen-
sure surveillance data have supported this ap-
proach.11,24-26,37 A further limitation of our trial 
involving young adults is the completion rate 
(2419 of 3304 participants, or 73.2%). This dis-
appointing completion rate may be attributable 
to the independence of this age group, which has 
characteristically low adherence to vaccination.38 
Despite a lower-than-desired completion rate, the 
criteria for success were met.
In conclusion, in two phase 3 trials involving 
adolescents and young adults, we found that 
MenB-FHbp was safe and immunogenic after 
dose 2 and dose 3. The vaccine was also associ-
ated with more injection-site reactions than hepa-
titis A virus vaccine and saline.
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